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Abstract
Cardiomyocytes compensate to acute cardiac stress by increasing in size and contractile function. However, prolonged
stress leads to a decompensated response characterized by cardiomyocyte death, tissue fibrosis and loss of cardiac function.
Identifying approaches to inhibit this transition to a decompensated response may reveal important targets for treating
heart failure. The Ral guanine nucleotide disassociation (RalGDS) proteins are Ras-interacting proteins that are upregulated
by hypertrophic stimuli. The Ral guanine nucleotide dissociation stimulator-like 2 (Rgl2) is a member of the RalGDS family
that modulates expression of hypertrophic genes in cardiomyocytes. However, the pathophysiologic consequence of
increased Rgl2 expression in cardiomyoctyes remains unclear. To evaluate the effect of increasing Rgl2 activity in the heart,
transgenic mice with cardiac-targeted over-expression of Rgl2 were generated. Although Ral activation was increased, there
were no apparent morphologic or histological differences between the hearts of Rgl2 transgenic and nontransgenic mice
indicating that increased Rgl2 expression had no effect on basal cardiac phenotype. To determine if Rgl2 modulates the
cardiac response to stress, mice were infused with the ß-adrenergic receptor agonist, isoproterenol. Isoproterenol infusion
increased heart mass in both Rgl2 transgenic and nontransgenic mice. However, unlike nontransgenic mice, Rgl2 transgenic
mice showed no morphologic evidence of cardiomyocyte damage or increased cardiac fibrosis following isoproterenol
infusion. Increased Rgl2 expression in cultured cardiomyocytes stimulated Ral activation and inhibited staurosporine-
induced apoptosis via increased activation of PI3-kinase. Activation of the PI3-kinase signaling pathway was confirmed in
hearts isolated from Rgl2 transgenic mice. Increased expression and function of Rgl2 in cardiomyocytes promotes activation
of the PI3-kinase signaling cascade and protects from carciomyocyte death and pathologic cardiac fibrosis. Taken further,
these results suggest that Rgl2 upregulation in hypertrophic hearts may be a protetive mechanism, and that Rgl2 may be a
novel therapeutic target in treating heart disease.
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Introduction
In response to stress, the heart maintains cardiac output through
a compensatory response that includes expression of fetal cardiac
genes, increased cardiomyocyte size and enhanced contractile
force (reviewed in [1,2,3]). Prolonged cardiac stress can lead to
cardiomyocyte death, cardiac fibrosis and a progressive loss of
cardiac function [4,5,6]. Inhibiting the transition from a compen-
sated to decompensated cardiac phenotype is key to understanding
and treating heart failure.
The monomeric GTP-binding protein Ras is a key regulator of
cell growth and function. Incubation of cardiomyocytes with
agonists that transiently activate Ras (e.g., insulin, phenylephrine)
induces cardiomyocyte growth and survival [7,8,9]. However, in
mice with cardiac targeted expression of a constitutively active Ras
(V12Ras), chronic Ras activation promotes cardiomyocyte hyper-
trophy, induction of hypertrophic genes and early lethal heart
failure [10,11]. Ras mediates its effects by interacting with several
effectors including Raf, PI3-kinase (PI3K), and Ral-GDS proteins.
In contrast to Raf and PI3K, which mediate cardiac hypertrophy
with preserved contractile activity and function [8,12,13,14], the
potential role of Ral-GDS proteins in cardiac hypertrophy is not
well defined.
The RalGDS family includes Ral-GDS, Rgl, Rgl2 and Rgl3
(reviewed in [15]). Rgl2, also referred to as the Ral guanine
nucleotide dissociation stimulator-like 2 (Rlf), was identified in a
yeast two hybrid screen of a cardiac cDNA library as a Ras-
interacting protein in the heart [16]. In neonatal rat ventricular
myocytes (NRVMs), expression of Rgl2 transactivated the atrial
natriuretic peptide and myosin light chain promoters, and
potentiated phenylephrine-mediated gene expression [16]. These
results indicate that Rgl2 is a novel regulator of transcriptional
responses in cardiomyocytes. A role for Ral-GDS and Ral
activation in cardiomyocyte hypertrophy is further supported by
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the findings that hypertrophic agents increased RalGDS expres-
sion in cardiomyocytes, expression of constitutively-active Ral
induced cardiomyocyte hypertrophy and Ral activity is increased
in hypertrophied hearts [17].
The aim of this study was to investigate the effect of increased
expression of the Ral-GDS family member, Rgl2, in the hearts of
transgenic mice and isolated cardiomyocytes. Results obtained
using both transgenic mice with cardiac-targeted Rgl2 expression
(Rgl2-Tg) and adenoviral-mediated expression of Rgl2 in cultured
cardiomyocytes identify a novel cardioprotective effect of Rgl2
mediated by activation of the PI3K/Akt signaling pathway.
Materials and Methods
Ethics Statement
All animal studies were carried out under the approval and
supervision of the Division of Laboratory Animal Research
Committees of the University of Kentucky (protocol #00670)
and the University of Arkansas for Medical Sciences (protocol
#3225), in accordance with the National Institutes of Health
(NIH) Guidelines for the Care and Use of Laboratory Animals.
Rgl2 Transgenic Mice
cDNA for the mouse ortholog of Rgl2 (i.e., Rlf) with a
hemagglutinin epitope (HA) tag was provided by Dr. Rob
Wolthuis (The Netherlands Cancer Institute, Amsterdam). This
sequence was subcloned into the mouse a-myosin heavy chain (a-
MyHC) promoter (provided by Dr. Jeffery Robbins, University of
Cincinnati) and used to generate transgenic mice (Rgl2-Tg) at the
University of Kentucky transgenic core facility. Genomic DNA
was isolated from founder mice and shown to express the expected
241 base pair DNA using primers specific for the a-MyHC
promoter and Rgl2 insert (forward, 59-ctg gtc aga cac ctc ttg ga-39;
reverse, 59-cct tga cct cag agc caa aa-39). Founders were bred with
Black Swiss mice and progeny screened for transgene transmission
via PCR. Two transgenic mouse lines, one of which was bred to
homozygosity, were used and yielded similar results. Results
obtained using mice that are homozygous for the Rgl2 transgene
are presented.
Generation of Rgl2 Antibody
A monoclonal antibody specific to wild-type Rgl2 was generated
in collaboration with BD Biosciences. Subsequently, a commer-
cially available Rgl2 antibody (Abcam) was used with identical
results.
Isoproterenol Infusion of Mice
Two-month-old male transgenic and non-transgenic littermates
were anesthetized with an intraperitoneal injection of ketamine
(0.0065 mg/g) and xylazine (0.013 mg/g). Mini-osmotic pumps
(model 2002, AlzetH) filled with either 0.02% ascorbic acid (AA,
vehicle control) or isoproterenol (Sigma Chemical) were implanted
subcutaneously via a small mid-scapular incision. The concentra-
tion of isoproterenol was calculated to deliver an average of
30 mg/kg/day during the infusion period. After 14 days of
continuous infusion, the mice were anesthetized, hearts rapidly
excised rinsed in ice cold saline, and then processed for histological
or biochemical analysis.
For histological examination, excised hearts were bisected, fixed
with 10% buffered formalin, embedded in paraffin, and sectioned
at 4 mm thicknesses. Sections were stained with hematoxylin and
eosin (H&E) for morphologic evaluation, modified elastic tri-
chrome for evaluation of collagen, or incubated with an anti-HA
rabbit polyclonal antibody (Upstate, Lake Placid, NY) followed by
a peroxidase-conjugated secondary antibody for immunohisto-
chemical detection of Rgl2. Images of trichrome stained slides
were digitally captured using an AperioH Scanscope (Aperio,
Vista, CA) and area of fibrosis quantified using the Aperio color
deconvolution algorithm. H&E-stained slides were examined and
myocyte vacuolation was graded on a scale of 0 (no vacuolization)
to 4 (severe vacuolization) by a veterinary pathologist who was
blinded to treatment and genotype. Cross-sectional area of
myocytes was determined using Image Pro Plus software (Media
Cybernetics).
For biochemical analysis, cardiac tissue homogenates were
prepared by rapidly freezing ventricular tissue in liquid nitrogen. A
hammer pre-chilled in liquid nitrogen was used to pulverize
ventricles into a fine powder. The powdered hearts were
suspended in 1 mL of MBST/OG buffer [25 mM MES,
150 mM NaCl, 60 mM octyglucopyranoside, 1% Triton-X100,
pH 6.4, and protease/phosphatase inhibitors (Pierce)], homoge-
nized with an ultrasonic homogenizer, and incubated on ice for 30
minutes. Lysates were cleared of non-soluble material by
centrifugation at 3006g for 3 minutes at 4uC and the protein
concentration determined using the DC Lowry protein assay
(BioRad) with BSA as a standard. Subsequently, equal amounts of
protein were resolved by 12% SDS-PAGE. Western blot analysis
was performed using antibodies to: Akt; phosphoSer473-Akt; the
active (cleaved) and full-length (procaspase-3) forms of caspase-3;
rabbit polyclonal Bax antibody, or rabbit polyclonal Bcl-xL
antibody (Cell Signaling, Danvers, MA), and the appropriate
species-specific horseradish peroxidase (HRP)-conjugated second-
ary antibody (Cell Signaling). Immunoreactive bands were
visualized using enhanced Super Signal West Pico chemilumine-
sence (Pierce Biotechnology) and band intensity quantified using a
Kodak Image Station.
Generation of Adenoviral Vectors
HA tagged-Rgl2 cDNA was subcloned into an adenoviral
backbone plasmid, AdEasy-1 (Stratagene) and recombinant
adenoviral plasmids transfected into HEK293 cells. The resulting
viral particles (AdRgl2) were purified by gradient centrifugation
and viral infectivity (ifu/ml) determined (Biogenesis Adenovirus).
Adenovirus lacking the Rgl2 insert (AdNull) was provided by Dr.
Nancy Webb (University of Kentucky, Lexington, KY).
Isolation and Culture of Cardiomyocytes
Neonatal Rat Ventricular Myocytes (NRVMs) were isolated
from 1–2 day old Sprague-Dawley rats according to a previously
described protocol with modifications [18]. Briefly, hearts were
excised and enzymatically digested at 37uC for 2 hours with
collagenase type II (Worthington) and pancreatin (Sigma).
Following tissue digestion, the isolated cells were incubated in an
uncoated flask for 2 hours to allow for the attachment of non-
myocyte cells. The subsequent cardiomyocyte-enriched suspension
was plated at a density of 0.36106 to 0.56106 cells/ml on gelatin-
coated plates and maintained at 37uC under 5% CO2 in DMEM/
Medium 199 containing 10% equine serum, 5% fetal bovine
serum (FBS), and penicillin/streptomycin (Invitrogen). Cardiomy-
ocytes were allowed to attach for 24 hours, washed, and
maintained in culture for an additional 24 hours prior to
adenoviral infection.
HL-1 cardiomyocytes were provided by Dr. William Claycomb
(Louisiana State University Medical Center, New Orleans, LA)
and maintained in culture as previously described [19]. HL-1
cardiomyocytes were grown to 1.0–1.56106 cells/well in 6-well
culture plates prior to adenoviral infection.
Rgl2 Promotes Cardiomyocyte Survival
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Cardiomyocyte Infection and Treatment
Cardiomyocytes (NRVMs or HL-1) were incubated with
AdRgl2 or AdNull virus (90 ifu/cell) in serum-free media. After
2 hours, FBS was added to the media at a final concentration of
1% (NRVMs) or 5% (HL-1s) and the incubation continued
overnight. Infection of either NRVMs or HL-1 cardiomyocytes
with 90 ifu/cell resulted in an infection efficiency of ,80%
without affecting cell viability, as assessed by trypan blue exclusion
(data not shown). Cardiomyocytes were then washed and
maintained in media without serum for 2 hours prior to treatment
with wortmannin (200 nM; Biomol), staurosporine (1 mM; Bio-
mol), or the appropriate vehicle for the indicated time prior to cell
lysis.
Following infection and treatment with pharmacological agents
or vehicle, cardiomyocytes were lysed for 30 minutes on ice in
MBST/OG buffer. The protein concentration of each superna-
tant was determined using the DC Lowry protein assay and equal
amounts of lysate protein resolved by 12% SDS-PAGE. For
NRVM samples treated with staurosporine, cardiomyocytes were
lysed directly in Laemmli sample buffer and resolved by 4–12%
gradient SDS-PAGE. Western blot analysis was performed using
antibodies to: Akt; phosphoSer473-Akt; the active (cleaved) and full-
length (procaspase-3) forms of caspase-3; and PARP (Cell
Signaling) and the appropriate species-specific horseradish perox-
idase (HRP)-conjugated secondary antibody (Cell Signaling).
Immunoreactive bands were visualized using enhanced Super
Signal West Pico chemiluminesence (Pierce Biotechnology) and
band intensity quantified using a Kodak Image Station. The
intensity of immunoreactive bands was normalized to a control
protein as indicated in the figure legends.
Ral Activation Assay
To assess Ral activation in cardiac tissue and cardiomyocytes,
homogenates or cardiomyocytes (lysed in buffer containing
25 mM Tris-HCL, pH 7.5, 40 mM NaCl, 30 mM MgCl2, 1%
Ipegal, 1 mM DTT, and protease/phosphatase inhibitors) were
incubated with a GST fusion protein which specifically binds to
the active, GTP-bound form of Ral (GST-RalBD; provided by Dr.
Doug Andres, University of Kentucky, Lexington, KY) as
previously described [16,20]. Briefly, ventricular homogenates or
cardiomyocyte lysates (500 mg) were incubated with GST-RalBD
bound agarose beads for 1 hour at 4uC with gentle rotation. The
beads were washed, proteins resolved by 12% SDS-PAGE, and
Ral detected using a RalA-specific antibody (BD Bioscience). The
relative amount of active Ral (Ral-GTP) was determined by
normalizing to total Ral detected in the lysate.
Statistical Analysis
Experiments performed with Rgl2 transgenic mice were
repeated in two lineages with similar results. Results are reported
as mean 6 standard error (SEM). A significant difference between
treatment groups was determined by t-test for individual
comparisons or for multiple comparisons by one-way ANOVA
and the post-hoc test indicated in legends. All analyses were
completed using GraphPad Prism software. Statistical significance
was accepted for p,0.05.
Results
Rgl2 was identified as a Ras interacting protein in the human
heart that potentiated transcriptional activation of hypertrophic
genes in cultured NRVMs [16]. To correlate these previous
findings with the in vivo effects of Rgl2, the a-MyHC promoter
was used to express the cDNA for HA-tagged Rgl2 in the hearts of
transgenic mice. The hearts of Rgl2 transgenic (Rgl2-Tg) and
nontransgenic (NTg) mice showed no gross morphologic differ-
ences at 2 months of age (Figure 1A) or at 12 months (data not
shown). Western blot analysis using a Rgl2-specific antibody
(Figure 1B) showed increased Rgl2 protein expression in cardiac
tissue of Rgl2-Tg mice, confirming transgene expression. Immu-
nohistochemical analysis of ventricular tissue using an antibody to
the HA-epitope verified transgenic protein (HA-Rgl2) expression
specifically in cardiac myofibrils of the Rgl2-Tg mice (Figure 1C).
Rgl2 promotes the exchange of GTP for GDP on the
monomeric G protein Ral. Therefore, to verify functionality of
the expressed Rgl2 protein, Ral-GTP levels in the hearts of Rgl2-
Tg and NTg mice were quantified using an affinity isolation assay
for activated Ral [16,20]. GTP-bound active Ral was isolated from
ventricular homogenates using an immobilized GST-Ral binding-
domain fusion protein, which only associates with GTP-bound
(i.e., active) Ral protein. The isolated proteins were immuno-
blotted with Ral-specific antibody to quantify the amount of
activated Ral protein. Compared to controls, Ral activation was
increased (2–3-fold) in the hearts of Rgl2-Tg mice (Figure 2).
Western blots of cardiac homogenates indicated that Rgl2-
mediated increases in Ral-GTP were not associated with increased
Ral protein levels.
The results presented above suggest that increased expression
and function of Rgl2 alone does not alter cardiac morphology. To
determine if increasing Rgl2 expression alters the response of
cardiomyocytes to increased stress, 2-month old Rgl2-Tg and NTg
mice were continuously infused for 2 weeks with the ß-adrenergic
receptor (ß-AR) agonist isoproterenol (ISO; 30 mg/kg/day) or
vehicle (AA; ascorbic acid). Isoproterenol-infused animals are a
commonly used cardiac stress model for studying cardiac
hypertrophy and inducing cardiac dysfunction [21,22,23,24].
Compared to vehicle infused mice, isoproterenol infusion
increased the heart weight to body weight ratio and heart weight
normalized to tibia length (data not shown) to the same extent in
NTg and Rgl2-Tg mice (Figure 3A). Isoproterenol-induced
increased heart sized was paralleled by an increase in cardiomy-
ocyte cross-sectional area (Figure 3B). However, compared to
vehicle infused mice, hearts prepared from isoproterenol-infused
NTg mice displayed increased collagen deposition (black arrows)
indicating increased fibrosis (Figure 3C and D) and cardiomy-
ocyte vacuolization (yellow arrows), indicating increased cardio-
myocyte injury (Figure 3C and E). Increased cardiomyocyte
injury was assoicated with an increase in apoptotic index (Bax/
Bcl-xl ratio) indicating an increase in cardiomyocyte apoptosis
(Figure 3F). In contrast, Rgl2-Tg hearts displayed no significant
increases in fibrosis, vacuolization, or apoptotic index following
isoproterenol treatment. These data indicate that increased Rgl2
expression does not affect ß-AR-induced increases in cardiac mass;
however, Rgl2 expression protects from ß-AR-induced cardiomy-
ocyte injury, apoptosis, and increased cardiac fibrosis.
To assess the mechanism by which increased Rgl2 expression in
cardiomyocytes protects from ß-AR-induced cardiac injury, HA-
Rgl2 was expressed in cultured NRVMs and HL-1 cells, a
commonly used cardiomyocyte cell line that retains the molecular
and functional properties of primary adult cardiomyocytes.
NRVMs and HL-1 cells were infected with a control adenovirus
(AdNull) or with adenovirus encoding HA-Rgl2 (AdRgl2).
Compared to AdNull-infected cells, infection of NRVMs
(Figure 4A) or HL-1 cells (Figure 4B) with AdRgl2 increased
Rgl2 protein expression. As shown for ventricular homogenates
prepared from Rgl2-Tg mice, activated, GTP-bound Ral was
significantly increased in both AdRgl2-infected NRVMs
(Figure 4C) and HL-1 cells (Figure 4D) compared to AdNull-
Rgl2 Promotes Cardiomyocyte Survival
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infected cardiomyocytes. There was no effect on total Ral protein
expression in either cell system. These results are consistent with
the previously described ability of Rgl2 to enhance guanine
nucleotide exchange on Ral and confirm expression of functional
Rgl2 protein in cardiomyocytes following adenoviral infection.
The effect of increased Rgl2 on cardiomyocyte apoptosis was
examined by incubating AdNull- or AdRgl2-infected cardiomyo-
cytes with staurosporine, an activator of apoptotic signaling
pathways [25]. Apoptosis was assessed by quantifying the active,
cleaved form of caspase-3, and cleavage of its downstream effector
DNAse, poly (A-ribose) polymerase (PARP). Treatment of AdNull-
infected NRVMs (Figure 5A) and HL-1 cardiomyocytes
(Figure 5B and C) with staurosporine for 4 hours significantly
increased caspase-3 activation (Figures 5A and 5B) and PARP
cleavage (Figure 5C). Staurosporine-induced caspase-3 activation
and PARP cleavage was significantly decreased in AdRgl2-
infected cardiomyocytes indicating that increasing Rgl2 expression
promotes cardiomyocyte survival.
Activation of the PI3K/Akt signaling pathway has been
associated with increased myocardial cell survival in cell culture
models and increased cardiac function in transgenic mice
[7,8,9,12,13,14,26,27,28]. To determine the effect of Rgl2 on
the activation PI3K/Akt signaling pathway, NRVMs were
infected with AdNull or AdRgl2, and PI3K activation was assessed
Figure 1. Transgenic expression of Rgl2 in mice. A) Representa-
tive pictures of hearts from nontransgenic (NTg) and transgenic mice
with cardiac specific overexpression of Rgl2 (Rgl2-Tg). Ruler gradations
are 1 mm. Graph represents the mean 6 SEM from at least 4 different
aged-matched hearts. * denotes significant difference from NTg. B)
Tissue homogenates from hearts of NTg and Rgl2-Tg mice were probed
with an antibodies to the hemagglutinen (HA) epitope and Rgl2. Shown
are a representative blot from a single experiment and the mean6 SEM
(n= 3) of Rgl2 expression normalized to tubulin. * denotes significant
difference from NTg. C) Photomicrographs of histological sections of
ventricular tissue demonstrating Rgl2 expression in myofibrils of Rgl2-
Tg. The sections depicted in the left panels were incubated without
primary antibody and the right sections were incubated with a
polyclonal antibody to the HA epitope (2006magnification).
doi:10.1371/journal.pone.0073599.g001
Figure 2. Expression of Rgl2 activates Ral. Heart homogenates
from Rgl2-Tg and NTg littermate mice were prepared and the amount
of GTP-bound Ral (active) assessed by immunoblotting. Total Ral was
assessed on separate immunoblots. Total and GTP-bound Ral were
quantified and a representative image from a single experiment and the
means 6 SEM from at least 6 individual mice are shown. * denotes
significant difference from NTg.
doi:10.1371/journal.pone.0073599.g002
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by immunoblotting for the active, phosphorylated form of Akt. Akt
phosphorylation was significantly increased in AdRgl2-infected
NRVMs (Figure 6A) and HL-1 cardiomyocytes (Figure 6B)
compared to AdNull-infected controls. Furthermore, AdRgl2-
induced Akt phosphorylation was inhibited by wortmannin
(Figure 6C), confirming that Akt phosphorylation was PI3K-
dependent.
The contribution of PI3K/Akt activation in mediating protec-
tion of cardiomyocytes from staurosporine-induced injury was
assessed using the PI3K-specific inhibitor wortmannin (200 nM;
Wort). Rgl2-mediated reduction in caspase-3 and PARP cleavage
was abolished by pretreating NRVMs (Figure 7A) and HL-1 cells
(Figure 7B and C) with wortmannin, confirming that PI3K
activation is required for Rgl2-enhanced cell survival. Together,
these data indicate that Rgl2 promotes cardiomyocyte survival by
activating the PI3K/Akt signaling cascade.
Based on the findings in culture cardiomyocytes, we evaluated
PI3K activation in the hearts of NTg and Rgl2-Tg mice. As shown
in Figure 8, relative to NTg mice, there was a significant increase
in pAkt detected in homogenates prepared from Rgl2-Tg mice.
Thus, increasing Rgl2 expression enhanced activation of the
PI3K/Akt pathway in both isolated cardiomyoctyes and in hearts
of transgenic mice.
Figure 3. Effect of Rgl2 on isoproterenol induced cardiac hypertrophy. Rgl2-Tg and NTg littermates were continuously infused with
isoproterenol (30 mg/kg/day; ISO) or vehicle (ascorbic acid; AA) for 14 days via mini-osmotic pumps. The effect of isoproterenol infusion on cardiac
hypertrophy (A,B) and pathology (C–E) were determined. A) Heart weight (HW) and body weight (BW) were determined and are expressed as the
heart weight (HW) to body weight (BW) ratio. B) Cardiomyocyte cross-sectional area was quantified by morphometric analysis of individual cells and
expressed relative to untreated NTG mice. C) Pathological changes in hearts of Rgl2-Tg and NTg mice following infusion were assessed using a
modified elastic trichrome stain to visualize collagen (green). Shown are representative sections from two different hearts from NTg and Rgl2-Tg mice
at 2006magnification. Representative areas of fibrosis are indicated by black arrows, and myocyte vacuolization by yellow arrows. Fibrotic area (D)
and extent of vacuolization (E) were quantified by morphometric analysis. Results are expressed as the mean6 SEM obtained from at least 9 different
mice. F) Apoptotic index was determined by western blotting for Bax and Bcl-xl in left ventricular homogenates and expressed as the Bax/Bcl-xl ratio.
A representative blot of lysates from 3 mice of each treatment and graph of mean 6 SEM from 9 mice are shown. * denotes significant difference
from AA infused NTg mice using Dunnett’s multiple comparison test.
doi:10.1371/journal.pone.0073599.g003
Figure 4. Adenoviral-mediated expression of Rgl2 in cardiomyocytes. NRVMs (A and C) or HL-1 cardiomyocytes (B and D) were infected with
90 ifu/cell of AdNull or AdRgl2. After infection, cell lysates were prepared and analyzed for Rgl2 expression (A and B) via immunoblotting using Rgl2
antibodies, and function (C and D) by assessing Ral activation. Rgl2 expression was normalized to cyclophilin A (cycloA) or tubulin. Ral activation was
determined as described in Figure 2 and are presented as the ratio of values obtained in AdRgl2- to AdNull-infected cells. Shown are representative
immunoblots of a single experiment and the means 6 SEM of at least 4 separate experiments. * denotes significant difference from AdNull infected
cells.
doi:10.1371/journal.pone.0073599.g004
Rgl2 Promotes Cardiomyocyte Survival
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Discussion
In this study, we examined the function of the Ras effector
protein Rgl2 in the hearts of transgenic mice and in cultured
cardiomyocytes. Cardiac-specific expression of constitutively
Figure 5. Effect of Rgl2 on apoptotic pathways in cardiomyo-
cytes. AdNull- and AdRgl2-infected NRVMs (A) and HL-1s (B and C)
were treated with staurosporine (Staur, 1 mM) for 0, 2, and 4 hr.
Caspase-3 (A and B) and PARP (C) activation were determined by
immunoblot of cell lysates using antibodies to activated caspase-3,
procaspase-3, and PARP. Active (cleaved) caspase-3 and PARP densities
were normalized to total enzyme and are expressed relative to the
respective control value (0 hr Staur). Shown are representative
immunoblots from a single experiment and the means 6 SEM of at
least 3 separate experiments. * denotes significant difference compared
to AdNull infected cells.
doi:10.1371/journal.pone.0073599.g005
Figure 6. Effect of Rgl2 on the PI3K/Akt signaling pathway in
cardiomyocytes. Cell lysates were collected from AdNull or AdRgl2
infected NRVMs (A, C) or HL-1 cardiomyocytes (B) and immunoblotted
with antibodies for pAkt, total Akt, or tubulin. (A and B) Rgl2-induced
Akt phosphorylation was quantified and normalized to AdNull infected
cells. (C) AdNull and AdRgl2 infected NRVMs were treated with
wortmannin (Wort) for 30 min prior to preparing cell lysates. Shown
are representative immunoblots from a single experiment and mean 6
SEM of at least 3 separate experiments. * denotes significant difference
from AdNull infected cells.
doi:10.1371/journal.pone.0073599.g006
Rgl2 Promotes Cardiomyocyte Survival
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active Ras initially induces cardiac hypertrophy with a rapid
progression to decompensated heart failure [11]. Ral activity is
also increased in hypertrophic hearts and increasing Ral activity in
cardiomyocytes is sufficient to induce hypertrophy [17]. In
contrast, our findings demonstrate that cardiac-targeted overex-
pression of Rgl2 has no apparent effect on either baseline cardiac
phenotype or the increased heart mass following chronic
isoproterenol infusion. Together, these findings suggest that Rgl2
does not change the basal cardiac phenotype or alter the
compensatory increase in heart size resulting from stress induced
by chronic ß-adrenergic receptor activation.
Cardiomyocyte injury and resultant interstitial fibrosis are
important contributing factors leading to decreased cardiac
function associated with multiple pathological conditions, includ-
ing ischemia-reperfusion injury and heart failure [6,29,30].
Chronic ß-AR receptor activation induces cardiac hypertrophy,
cardiomyocyte death and subsequent interstitial fibrosis
[21,22,23]. Consistent with these reports, we found increased
cardiac fibrosis, cardiomyocyte vacuolization and apoptosis in
NTg mice infused with isoproterenol for two weeks. In contrast,
the hearts of Rgl2-Tg mice exhibited significantly less isoproter-
enol-induced cardiac fibrosis, cardiomyocyte vacuolization and
apoptosis indicating that increased Rgl2 activation may be
cardioprotective.
To facilitate mechanistic studies of how Rgl2 mediates its
cardioprotective effects, we used an adenoviral delivery approach
to increase Rgl2 expression and function in primary NRVMs and
in cultured HL-1 cardiomyocytes. In both cardiomyocyte model
systems, infection with adenovirus encoding Rgl2 increased PI3K
activity and decreased staurosporine-induced apoptosis, as assessed
by decreased PARP and/or caspase-3 cleavage. Pharmacological
inhibition of PI3K with wortmannin abolished Rgl2-induced Akt
phosphorylation as well as Rgl2-mediated inhibition of caspase
activation, demonstrating that PI3K activation mediates the
Figure 7. Effect of Rgl2 on staurosporine-induced caspase-3
and PARP cleavage. AdNull- and AdRgl2-infected NRVM (A) and HL-1
cardiomyocytes (B and C) were pretreated with vehicle or 200 nM
wortmannin (Wort) for 30 min followed by exposure to 1 mM
staurosporine (Staur) for 0, 2, and 4 hr. Caspase-3 (A and B) and PARP
(C) cleavage were analyzed as described in Figure 5. Results are
presented normalized to the respective baseline value (0 hr Staur).
Values are expressed as mean6 SEM of at least 3 separate experiments.
* denotes significant difference from AdNull infected cells.
doi:10.1371/journal.pone.0073599.g007
Figure 8. Effect of Rgl2 on the PI3K/Akt signaling pathway in
transgenic mice. Heart homogenates prepared from Rgl2-Tg and NTg
littermates were prepared and Akt phosphorylation quantified by
immunoblotting with a phosphospecific Akt antibody and normalizing
to total Akt. Shown are a representative immunoblot and the mean 6
SEM of 12 different homogenates. * denotes significant difference from
NTg.
doi:10.1371/journal.pone.0073599.g008
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observed anti-apoptotic effects of Rgl2. Modulation of the PI3K/
Akt pathway in cardiomyocytes is of particular interest due to its
well established role in promoting cardiomyocyte survival and
function [14,31,32,33,34,35]. For example, activation of the
PI3K/Akt signaling pathway has been shown to reduce apoptosis
and protect cardiac function following ischemic injury in both
in vitro and in vivo models [34,35,36]. Our data extend these
findings by demonstrating that increasing Rgl2 activity is a novel
approach to induce PI3K-mediated cardiomyocyte survival.
Although the increased expression of Rgl2 as achieved in this
study mediates a protective effect to cardiac stress, caution must be
taken in extrapolating our results to physiological conditions in
which Rgl2 expression is not upregulated. Exploring the physio-
logical roles of Rgl2 would require cardiac-targeted deletion of
Rgl2.
The intermediary signaling molecules that link Rgl2 to PI3K
and Akt phosphorylation in cardiomyocytes are not known. In
different cell systems, RalGDS has been shown to elicit both Ral-
dependent and Ral-independent effects [15,17,37,38]. For exam-
ple, growth factor receptor-induced phospholipase D (PLD)
stimulation is mediated by a RalGDS/RalA signaling pathway
in HEK293 cells [37], and increasing PLD activation has been
shown to enhance PI3K/Akt signaling [39,40,41,42] and mediate
cardioprotective effects [43,44]. Our results demonstrating that
Rgl2 enhanced RalA activation support the possibility of a RalA-
dependent mechanism for enhancing PI3K/Akt activation in
cardiomyocytes. The possibility that Rgl2 has Ral independent
effects in cardiomyocytes is supported by the previous finding that
increased Ral activity is sufficient to induce cardiomyocyte
hypertrophy [17] however, we saw no evidence that enhancing
Rgl2 expression induced cardiac hypertrophy. Additional evidence
for RalA-independent effects of Ral-GDS proteins include the
finding that some, but not all, RalGDS-induced signals can be
inhibited by a dominant-negative Ral [45], and that RalGDS
directly interacts with JIP1 and PKD to induce Akt phosphory-
lation [38]. Similar to our results, cardiac-specific Rho overex-
pression was recently shown to protect from ischemia/reperfusion
injury via activation of PKD [46]. Although our results do not
exclude a role for PKD, a similar direct interaction between Rgl2
and PKD is unlikely to explain the current results as Rgl2-
dependent Akt phosphorylation was inhibited by wortmannin
indicating the requirement for PI3K activation.
Conclusions
Overall, our results demonstrate the ability of Rgl2 to activate
the PI3K/Akt signaling pathway and enhance cardiomyocyte
survival without altering basal cardiac phenotype or the compen-
satory increase in cardiac mass following chronic ß-AR stimula-
tion. Future studies will examine the contribution of RalA-
dependent and RalA-independent signaling pathways in Rgl2-
induced activation of the PI3K/Akt signaling cascade, and
whether Rgl2 represents a novel therapeutic target in cardiac
disease.
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